Vivos Therapeutics(VVOS) - 2025 Q1 - Quarterly Results

Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated "Building on the pivotal changes we initiated in 2024, Vivos has continued to strategically position itself for growth in 2025. We've streamlined our operations and laid a rock-solid foundation for the future. The acquisition and integration of SCN will showcase our transformation, setting the stage for thousands of OSA patients to gain access to our devices from just this one acquisition. Coupled with the increasing adoption of our FDA-clea ...